Informatics Firms See FDA s Guidance Opening Pharmacogenomic Floodgate | GenomeWeb

In a move that was welcomed by pharmaceutical and biotech companies, the US Food and Drug Administration last week released for public comment its draft guidance on the submission of pharmacogenomic data. The guidance document is also good news for informatics firms who plan to bridge the genomics knowledge gap that exists between pharma and the FDA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.